HomeCompareEPZM vs EQR

EPZM vs EQR: Dividend Comparison 2026

EPZM yields 136.05% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPZM wins by $15.34M in total portfolio value
10 years
EPZM
EPZM
● Live price
136.05%
Share price
$1.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.39M
Annual income
$6,293,323.05
Full EPZM calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — EPZM vs EQR

📍 EPZM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPZMEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPZM + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPZM pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPZM
Annual income on $10K today (after 15% tax)
$11,564.63/yr
After 10yr DRIP, annual income (after tax)
$5,349,324.59/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EPZM beats the other by $5,344,670.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPZM + EQR for your $10,000?

EPZM: 50%EQR: 50%
100% EQR50/50100% EPZM
Portfolio after 10yr
$7.72M
Annual income
$3,149,399.33/yr
Blended yield
40.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

EPZM
Analyst Ratings
10
Buy
5
Hold
1
Sell
Consensus: Buy
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPZM buys
0
EQR buys
0
No recent congressional trades found for EPZM or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPZMEQR
Forward yield136.05%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$15.39M$47.8K
Annual income after 10y$6,293,323.05$5,475.61
Total dividends collected$14.14M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: EPZM vs EQR ($10,000, DRIP)

YearEPZM PortfolioEPZM Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$24,305$13,605.44$11,380$679.82+$12.9KEPZM
2$56,912$30,905.26$13,014$837.25+$43.9KEPZM
3$128,528$67,631.59$14,961$1,036.20+$113.6KEPZM
4$280,268$142,743.86$17,297$1,289.22+$263.0KEPZM
5$590,792$290,905.24$20,121$1,613.15+$570.7KEPZM
6$1,205,245$573,097.64$23,561$2,030.84+$1.18MEPZM
7$2,382,274$1,092,661.12$27,783$2,573.54+$2.35MEPZM
8$4,567,482$2,018,449.47$33,013$3,284.39+$4.53MEPZM
9$8,503,963$3,616,756.90$39,547$4,223.51+$8.46MEPZM
10$15,392,564$6,293,323.05$47,791$5,475.61+$15.34MEPZM

EPZM vs EQR: Complete Analysis 2026

EPZMStock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Full EPZM Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this EPZM vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPZM vs SCHDEPZM vs JEPIEPZM vs OEPZM vs KOEPZM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.